How Much Does Wegovy Cost for Teens? A Parent's Guide to GLP-1 Costs and Coverage

Medically Reviewed by: Dr. Makia Powers, MD, MPH, MSc, DABOM (Diplomate, American Board of Obesity Medicine)

Last reviewed: August 2026

Wegovy's price for a teen depends on your insurance, which savings program you use, and whether you are a new patient. As of mid-2026, families paying without insurance spent roughly $199 to $349 a month through Novo Nordisk's own programs — the $199 end is a new-patient promotional rate for the first two fills, while the standard price is about $349. The list price is much higher, close to $1,349 a month. Insurance coverage for teens is limited, so the real cost varies a lot from family to family.

Is Wegovy approved for teens?

Yes. Wegovy is FDA-approved for teens ages 12 and older who have obesity.

A GLP-1 is a class of weight-management medicines that work with your body's own hunger signals to lower appetite. Wegovy (the brand name for semaglutide) won FDA approval for this age group in December 2022. The approval is for teens with obesity, which doctors define as a body mass index (BMI) at or above the 95th percentile for a child's age and sex. In plain terms, that means a teen's BMI falls in the top 5 percent compared with other kids the same age and sex.

Wegovy is one of two GLP-1-class medicines approved for this age group:

• Wegovy (semaglutide): a weekly injection, approved for ages 12 and older.
• Saxenda (liraglutide): a daily injection, approved for ages 12 and older since December 2020.

One drug you may have heard of is not approved for teens. Zepbound (tirzepatide) is approved only for adults. Its label states that safety and effectiveness have not been established in patients under 18. A study in teens is underway, but for now Zepbound is not an option for this age group.

These medicines are prescription-only. A teen should start one only after a full evaluation by a doctor who treats childhood obesity.

How much does Wegovy cost for teens without insurance?

Without insurance, Wegovy's self-pay price runs roughly $199 to $349 a month through Novo Nordisk's own programs, and it changes over time. The $199 end is a new-patient promotional rate for the first two fills; most families pay about $349.

The price depends on which program you use and whether you are a new patient, and the $199 promotional rate in particular applies only to a new patient's first two fills at the starter doses (0.25 mg and 0.5 mg). The table below shows Novo Nordisk's official self-pay prices, offered through Novo Nordisk's patient-support program NovoCare, as of August 2026. Treat these as a snapshot, not a promise. The maker can change or cancel any of these offers, and several have set expiration dates.

Two points often confuse families:

• List price is not what you pay. You may see "$1,349 a month" quoted online. That is the sticker price. Almost no one paying cash pays that amount, because the maker's self-pay programs bring it down a lot.
• A savings card is not the same as self-pay. Novo Nordisk offers a savings card that can drop the cost to as little as $25 a month. But that card requires private (commercial) insurance and excludes people on government plans. So a teen on Medicaid or CHIP cannot use it. If you have no insurance, the cash route is the self-pay price above, not the $25 card.

Because these numbers move, check the official price on novocare.com before you make a decision. The dollar figures here reflect August 2026 and can change.

Does insurance cover Wegovy for teens?

Sometimes, but coverage for a teen's weight-management medicine is limited and varies a lot by plan. Many families are denied or face heavy paperwork first.

Why pediatric GLP-1 coverage is so limited

Weight-loss medicines sit in a benefit category that many health plans treat as optional. Large employer plans and marketplace (ACA) plans often exclude or restrict them for obesity. Even when a plan does cover the drug, it usually requires prior authorization first. Prior authorization is when your insurer must approve a medicine before they will pay for it. For a teen, that often means the doctor has to send proof of the diagnosis and supporting records, and the plan can still say no.

How rare is access in practice? A 2025 analysis of electronic health records found that fewer than 1 in 100 teens with obesity were prescribed a GLP-1. The study also found teens on Medicaid or paying cash were far less likely to get one than teens with private insurance. The authors tie this partly to coverage limits and prior-authorization rules. This study is a preprint, meaning it has not yet finished peer review. Read it as a signal of how hard access is, not as a coverage rate.

Medicaid, Medicare, and marketplace plans

Public coverage depends heavily on who pays and where you live:

• Medicare: By law, Medicare does not pay for drugs used for weight loss. This rarely affects teens, since Medicare mainly covers people 65 and older. We mention it only because "the government won't pay" is a common myth, and the rule that creates it is a Medicare rule.
• Medicaid: States choose whether to cover weight-loss drugs. As of January 2026, only 13 state Medicaid programs covered GLP-1 drugs for obesity. The rest did not, though they still cover these drugs for other approved uses like diabetes.
• A special rule for kids on Medicaid: A federal benefit called EPSDT can require Medicaid to cover care that is medically necessary for a child, even when the same benefit is optional for adults. This can help a teen's case. But it is not a guarantee. States and their plans still apply medical-necessity rules, step therapy, and prior authorization, so families may still face denials.

The honest takeaway: do not assume coverage. Call the number on your insurance card and ask directly whether your plan covers Wegovy for a teen, and what steps are required.

What are the ways families pay for a teen's GLP-1?

Families usually pay one of four ways: through insurance (if approved), through cash self-pay, with a savings card (private insurance only), or through a comprehensive care program that bundles the clinical support around the medicine.

Here is how those paths compare.

Notice that the first three paths pay for the medicine only. None of them include the clinical care that helps a teen use the medicine safely and well.

How does a comprehensive program like Blueberry Balance compare?

A comprehensive program wraps medical care, nutrition support, and monitoring around the medicine, which matches what pediatric guidelines recommend.

The American Academy of Pediatrics (AAP) is clear on this. Its 2023 guideline for treating childhood obesity says weight-management medicine should be an adjunct to intensive health behavior and lifestyle treatment, not a standalone fix. In plain language, the medicine works best as one part of a broader plan that includes nutrition, behavior support, and regular follow-up with a care team.

Pediatricians ... should offer adolescents 12 years and older with obesity weight loss pharmacotherapy ... as an adjunct to health behavior and lifestyle treatment.

American Academy of Pediatrics, 2023 Clinical Practice Guideline (Key Action Statement 12)

That guideline is exactly the gap a medicine-only path can leave open. A cash prescription gets you the drug. It does not get you the dietitian, the dose monitoring, or the follow-up visits that help a teen succeed and stay safe.

A medicine-only price also tends to hide real costs. Here is what is often left out.

Blueberry Balance is built to fill that gap. The Balance subscription is $149 a month and includes physician visits, dietitian visits, health coaching, and labs. Nutrition coaching from a registered dietitian is built into the program, so families do not have to find one on their own. Balance primarily prescribes the Wegovy injection, and that medication is a separate cost: about $199 a month for new patients (first two fills, through December 31, 2026), then about $349 a month at the standard self-pay price (verify current prices on novocare.com). Balance fills these prescriptions primarily through NovoCare's mail-order pharmacy. The cost also depends on your insurance or prior-authorization outcome. The program fee and the medicine are two different bills, never one combined price.

To be honest about it, Balance is not always the cheapest path. For a family whose insurance fully covers the GLP-1, paying through that plan may cost less. Balance is built for families who want medicine plus clinical care plus help navigating coverage in one place, especially when coverage is uncertain.

Which cost path is right for your family?

The right path depends on your insurance, your budget, and how much support you want around the medicine.

A few simple guideposts:

• If your plan clearly covers it: Paying through insurance may be your lowest-cost option. Confirm the copay and any prior-authorization steps first.
• If you have private insurance but are not sure about coverage: Ask your plan directly, and ask the prescriber's office to help with prior authorization.
• If you have no coverage or keep hitting denials: A comprehensive program can remove the guesswork by bundling the care and helping you navigate the drug cost.
• If cost is your only concern and you already have a care team: A maker's self-pay program may be the simplest route, as long as you understand the price can change.

There is no single best answer for every family. The best path is the one that keeps your teen safe, supported, and able to stay on track.

When to talk to a doctor about GLP-1s for your teen

Talk to a doctor if your teen has obesity and you are weighing a GLP-1, especially if you have already been told the medicine could help.

A good first step is a full evaluation with a doctor who treats childhood obesity. They can confirm whether a GLP-1 fits your teen, explain the risks and benefits, and start the insurance process. In our experience caring for Balance families, one of the most common questions parents ask is, "My teen's doctor recommended a GLP-1, but our insurance denied it, so what do we do now?" A denial is often the starting point, not the end of the road. The care team can file an appeal with added medical detail, which sometimes changes the answer.

Call your doctor promptly if your teen has any concerning symptoms while on a GLP-1, such as severe belly pain, repeated vomiting, or signs of an allergic reaction. When in doubt, reach out to your care team.

Frequently Asked Questions

Is Wegovy FDA-approved for teenagers, and at what age?

Yes. Wegovy is approved for teens ages 12 and older who have obesity (a BMI at or above the 95th percentile for age and sex). It has held this approval since December 2022.

How much does Wegovy cost per month for a teen without insurance?

As of mid-2026, Novo Nordisk's self-pay programs ran roughly $349 a month at the standard self-pay price, or about $199 for a new patient's first two fills (a promotional rate through December 31, 2026). The list price was about $1,349 a month. These numbers change, so verify the current price on novocare.com.

Does insurance cover Wegovy for adolescents?

Sometimes, but coverage is limited and varies by plan. Many plans exclude or restrict weight-management drugs, and most require prior authorization. Call your insurer to ask about your specific plan.

Do Medicaid and Medicare cover GLP-1s for teens?

Medicare does not cover drugs for weight loss by law, and it rarely applies to teens anyway. Medicaid depends on your state; as of January 2026, only 13 state programs covered GLP-1 drugs for obesity. A federal rule called EPSDT can help a child's case but does not guarantee approval.

Can teens use a manufacturer savings card?

Only if they have private (commercial) insurance. The savings card excludes people on government plans, so a teen on Medicaid or CHIP cannot use it.

Is the cheapest path always the best path for a teen?

Not necessarily. Pediatric guidelines say weight-management medicine works best as one part of a full care program with nutrition support and follow-up. A medicine-only path can skip the care that helps a teen succeed safely.

A note on costs and coverage

This article is for general education and is not medical advice. Prices, programs, and coverage rules change often. Always confirm coverage with your specific plan, and talk with your pediatrician about what is right for your teen.

Sources

• FDA, Wegovy Prescribing Information (pediatric 12+ indication): https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf
• FDA, News release on Saxenda approval for ages 12 and older (Dec 2020): https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-weight-management-drug-patients-aged-12-and-older
• Eli Lilly, Zepbound Prescribing Information (not established under 18): https://pi.lilly.com/us/zepbound-uspi.pdf
• American Academy of Pediatrics, 2023 Clinical Practice Guideline (Executive Summary): https://publications.aap.org/pediatrics/article/151/2/e2022060641/190440/
• Novo Nordisk / NovoCare, Wegovy self-pay price guide (accessed August 2026): https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
• HHS / ASPE, Medicare Coverage of Anti-Obesity Medications: https://aspe.hhs.gov/sites/default/files/documents/127bd5b3347b34be31ac5c6b5ed30e6a/medicare-coverage-anti-obesity-meds.pdf
• KFF, Medicaid Coverage of and Spending on GLP-1s (13 states, as of Jan 2026): https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
• medRxiv preprint, Prescribing of GLP-1 Receptor Agonists for Adolescents with Obesity and Associated Disparities (2025): https://www.medrxiv.org/content/10.1101/2025.10.06.25337411